Journal of Clinical Oncology Publishes Clinical Results Of Adagrasib As A Targeted Treatment For KRASG12C-Mutated NSCLC With Untreated Central Nervous System Metastases
Portfolio Pulse from Happy Mohamed
Mirati Therapeutics' adagrasib, a KRASG12C inhibitor, demonstrated durable intracranial activity in patients with KRASG12C-mutated NSCLC with untreated CNS metastases in the KRYSTAL-1 study. The Journal of Clinical Oncology published the results, which follow adagrasib's recent inclusion in the NCCN guidelines for CNS Cancers.
June 20, 2023 | 12:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mirati Therapeutics' adagrasib demonstrated promising results in the KRYSTAL-1 study for KRASG12C-mutated NSCLC with untreated CNS metastases, potentially leading to increased adoption and revenues.
The positive results from the KRYSTAL-1 study demonstrate adagrasib's effectiveness in treating KRASG12C-mutated NSCLC with untreated CNS metastases. This could lead to increased adoption of the drug, inclusion in more guidelines, and ultimately higher revenues for Mirati Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100